Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma

A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma ORIGINAL ARTICLE A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma Svetomir N. Markovic, MD, PhD,*† Vera J. Suman, PhD,‡ Ravi A. Rao, MD,* James N. Ingle, MD,* Judith S. Kaur, MD,* Lori A. Erickson, MD,§ Henry C. Pitot, MD,* Gary A. Croghan, MD, PhD,* Robert R. McWilliams, MD,* Jaime Merchan, MD,* Lisa A. Kottschade, RN, MSN, CNP,* Wendy K. Nevala, BS,† Cindy B. Uhl, BS,† Jacob Allred, MS,† and Edward T. Creagan, MD* hrombospondin-1 (TSP-1) is a naturally occurring inhib- Objectives: Thrombospondins are natural inhibitors of angiogene- Titor of angiogenesis secreted by epithelial cells as part of sis, tumor metastases, and tumor growth (melanoma). ABT-510 is a the cytokine microenvironment involved in the organization synthetic analog of thrombospondin-1, well tolerated in phase I of perivascular matrix of tissues. TSP-1 has been shown to studies. We conducted a phase II trial evaluating the clinical efficacy significantly down-regulate a range of functions of activated of ABT-510 and its effects on biomarkers of angiogenesis and endothelial cells with direct impact on tumor growth and immunity in patients with metastatic melanoma (MM). 1–3 dissemination. A number of synthetic TSP-1 analogs have Patients and Methods: A 2-stage phase http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Clinical Oncology Wolters Kluwer Health

A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/a-phase-ii-study-of-abt-510-thrombospondin-1-analog-for-the-treatment-eqsKVcPKcu

References (68)

ISSN
0277-3732
eISSN
1537-453X
DOI
10.1097/01.coc.0000256104.80089.35
pmid
17551310
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma Svetomir N. Markovic, MD, PhD,*† Vera J. Suman, PhD,‡ Ravi A. Rao, MD,* James N. Ingle, MD,* Judith S. Kaur, MD,* Lori A. Erickson, MD,§ Henry C. Pitot, MD,* Gary A. Croghan, MD, PhD,* Robert R. McWilliams, MD,* Jaime Merchan, MD,* Lisa A. Kottschade, RN, MSN, CNP,* Wendy K. Nevala, BS,† Cindy B. Uhl, BS,† Jacob Allred, MS,† and Edward T. Creagan, MD* hrombospondin-1 (TSP-1) is a naturally occurring inhib- Objectives: Thrombospondins are natural inhibitors of angiogene- Titor of angiogenesis secreted by epithelial cells as part of sis, tumor metastases, and tumor growth (melanoma). ABT-510 is a the cytokine microenvironment involved in the organization synthetic analog of thrombospondin-1, well tolerated in phase I of perivascular matrix of tissues. TSP-1 has been shown to studies. We conducted a phase II trial evaluating the clinical efficacy significantly down-regulate a range of functions of activated of ABT-510 and its effects on biomarkers of angiogenesis and endothelial cells with direct impact on tumor growth and immunity in patients with metastatic melanoma (MM). 1–3 dissemination. A number of synthetic TSP-1 analogs have Patients and Methods: A 2-stage phase

Journal

American Journal of Clinical Oncology – Wolters Kluwer Health

Published: Jun 1, 2007

There are no references for this article.